Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.63 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.63 |
| ▸ | MAP3K5 | Q99683 | 4/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.61 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.60 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.60 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16496688 | 1.00 | STAT3 (1.00) | STAT3APEX1PSMB8HIF1ANMAP3K5 | |
| SCHEMBL3893592 | 0.89 | STAT3 (0.81) | STAT3APEX1HIF1ANMAP3K5PTPN22 | |
| SCHEMBL3893598 | 0.89 | STAT3 (0.81) | STAT3APEX1HIF1ANMAP3K5PTPN22 | |
| SCHEMBL5146772 | 0.89 | STAT3 (0.80) | STAT3PSMB8ENPP2PTPN22MEN1 | |
| SCHEMBL5146767 | 0.89 | STAT3 (0.80) | STAT3PSMB8ENPP2PTPN22MEN1 | |
| SCHEMBL12812670 | 0.88 | STAT3 (0.78) | STAT3HIF1ANMAP3K5PTPN22TNFRSF1A | |
| SCHEMBL30657755 | 0.88 | APEX1 (0.82) | STAT3APEX1MAP3K5PTPN22MEN1 | |
| SCHEMBL3131544 | 0.88 | STAT3 (0.78) | STAT3APEX1HIF1ANMAP3K5TNFRSF1A | |
| SCHEMBL3131549 | 0.88 | STAT3 (0.78) | STAT3APEX1HIF1ANMAP3K5TNFRSF1A | |
| SCHEMBL3131533 | 0.88 | STAT3 (0.78) | STAT3APEX1HIF1ANMAP3K5TNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296270-A1 | STAT3 Inhibitors | BAYLOR COLLEGE OF MEDICINE (US) | 2014-10-02 | — | — | US | claimed |
| US-20110312984-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | claimed |
| EP-2299999-A1 | STAT3 INHIBITORS | Baylor College Of Medicine (US) | 2011-03-30 | — | — | EP | claimed |
| US-20100041685-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | claimed |
| WO-2009149192-A1 | STAT3 INHIBITORS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-12-10 | — | — | WO | claimed |
| US-20230159629-A1 | COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230077280-A1 | THERAPEUTIC COMPOUNDS FOR METHODS OF USE IN INSULIN RESISTANCE | TVARDI THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| EP-4082538-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | Baylor College of Medicine (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-4069287-A1 | THERAPEUTIC COMPOUNDS FOR METHODS OF USE IN INSULIN RESISTANCE | Baylor College of Medicine (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-115023236-A | Therapeutic compounds for methods of use of insulin resistance | 贝勒医学院 | 2022-09-06 | — | — | CN | disclosed |
| US-11406707-B2 | STAT3 phosphorylation during graft-versus-host disease | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220227750-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ANAPHYLAXIS | BAYLOR COLLEGE OF MEDICINE (US) | 2022-07-21 | — | — | US | disclosed |
| WO-2015010107-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015010106-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | BAYLOR COLLEGE OF MEDICINE (US) | 2015-01-22 | — | — | WO | disclosed |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2015-01-22 | — | — | US | disclosed |
| US-20140296270-A1 | STAT3 Inhibitors | BAYLOR COLLEGE OF MEDICINE (US) | 2014-10-02 | — | — | US | disclosed |
| US-8779001-B2 | Stat3 inhibitors | The United States of America National Institute of Health (NIH) (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130202612-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE CONDITIONS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20110312984-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| US-20100041685-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | STAT3 3/4885APEX1 4118/4885PSMB8 3236/4885 |
| US-20100041685-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | STAT3 1/4885APEX1 3534/4885PSMB8 2588/4885 |
| US-20230077280-A1 | THERAPEUTIC COMPOUNDS FOR METHODS OF USE IN INSULIN RESISTANCE | GPR119, GCKR, GLS2 | STAT3 4/4885APEX1 2776/4885PSMB8 3681/4885 |
| US-11406707-B2 | STAT3 phosphorylation during graft-versus-host disease | STAT3, STAT1, STAT5B | STAT3 1/4885APEX1 2649/4885PSMB8 2745/4885 |
| US-20220227750-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ANAPHYLAXIS | CMA1, CPA3, STAT6 | STAT3 4/4885APEX1 2660/4885PSMB8 2630/4885 |
| US-20140296270-A1 | STAT3 Inhibitors | STAT3, STAT1, JAK2 | STAT3 1/4885APEX1 3534/4885PSMB8 2588/4885 |
| US-20110312984-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | STAT3 1/4885APEX1 3534/4885PSMB8 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.